Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
ND Regulators Approve Bank-to-Bank Stablecoin Use North Dakota’s Industrial Commission approved the use of the state bank’s planned stablecoin, the Roughrider Coin, for bank-to-bank transactions...
Tech Group Pushing Back on NY Chatbot Bill A tech industry group is opposing a New York bill ( SB 7263 ) aimed at preventing chatbots from impersonating a variety of licensed professionals, including...
KS Lawmakers Pass PBM Bill A bill aimed at tightening regulations on PBMs ( SB 360 ), but which appeared unlikely to move forward this session, was inserted into another bill ( SB 20 ) during a conference...
Who could have predicted this? Prediction markets have emerged as one of the biggest stories of 2026. The online platforms and apps, which allow users to bet on anything from who will win the Oscar for...
New White House Policy Framework Calls for Blocking State AI Laws The Trump administration released a National Policy Framework for Artificial Intelligence that, among other things, urges Congress to...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
A bill (SB 410) debated in the Michigan Senate last week would allow residents and state and local governments to sue drug manufacturers and sellers if their products cause injury. In 1995 the state passed the strongest drug immunity law in the nation, shielding drugmakers and sellers almost entirely from such suits. (BRIDGE MICHIGAN)
This year at least 24 states have enacted legislation dealing with health system consolidation and competition, according to the National Conference of State Legislatures. Among many other things the measures address the review and approval of health system mergers, reforms of health system contracting and certificate of need review. (NCSL)
California Gov. Gavin Newsom vetoed a bill (SB 90) that would have prohibited insurers from charging consumers more than $35 out of pocket for a 30-day supply of insulin. Earlier this year the governor announced the state would be partnering with the nonprofit pharmaceutical company Civica Rx to produce its own insulin, which it plans to sell for $30. (ASSOCIATED PRESS, STATE NET)
American taxpayers are overpaying for Medicare Advantage, or Medicare Part C—under which insurance companies are paid by the federal government to manage patient care—by at least $88 billion per year and possibly as much as $140 billion per year, according to a report published by Physicians for a National Health Program. “Various elements of MA, either by design or by consequence, result in a much higher level of government spending than is necessary to provide Medicare benefits, with much of this money going toward corporate profits,” the report states. (MEDICAL ECONOMICS)
—Compiled by SNCJ Managing Editor KOREY CLARK